JP2015044803A - 画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム - Google Patents

画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム Download PDF

Info

Publication number
JP2015044803A
JP2015044803A JP2014153847A JP2014153847A JP2015044803A JP 2015044803 A JP2015044803 A JP 2015044803A JP 2014153847 A JP2014153847 A JP 2014153847A JP 2014153847 A JP2014153847 A JP 2014153847A JP 2015044803 A JP2015044803 A JP 2015044803A
Authority
JP
Japan
Prior art keywords
tumor
radioactivity accumulation
radioactivity
radioactive
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014153847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015044803A5 (https=
Inventor
務 阿部
Tsutomu Abe
務 阿部
信弥 小橋
Shinya Kobashi
信弥 小橋
俊介 女池
Shunsuke Meike
俊介 女池
侑紀 奥村
Yuki Okumura
侑紀 奥村
博樹 松本
Hiroki Matsumoto
博樹 松本
裕司 久下
Yuji Kuge
裕司 久下
松吉 趙
Matsuyoshi Cho
松吉 趙
剣一 西嶋
Kenichi Nishijima
剣一 西嶋
一枝 大倉
Kazue Okura
一枝 大倉
宏行 秋澤
Hiroyuki Akisawa
宏行 秋澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIGASHI NIPPON GAKUEN
Nihon Medi Physics Co Ltd
Hokkaido University NUC
Original Assignee
HIGASHI NIPPON GAKUEN
Nihon Medi Physics Co Ltd
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIGASHI NIPPON GAKUEN, Nihon Medi Physics Co Ltd, Hokkaido University NUC filed Critical HIGASHI NIPPON GAKUEN
Priority to JP2014153847A priority Critical patent/JP2015044803A/ja
Publication of JP2015044803A publication Critical patent/JP2015044803A/ja
Publication of JP2015044803A5 publication Critical patent/JP2015044803A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
JP2014153847A 2013-07-30 2014-07-29 画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム Pending JP2015044803A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014153847A JP2015044803A (ja) 2013-07-30 2014-07-29 画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013157323 2013-07-30
JP2013157323 2013-07-30
JP2014153847A JP2015044803A (ja) 2013-07-30 2014-07-29 画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム

Publications (2)

Publication Number Publication Date
JP2015044803A true JP2015044803A (ja) 2015-03-12
JP2015044803A5 JP2015044803A5 (https=) 2017-08-17

Family

ID=52670659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014153847A Pending JP2015044803A (ja) 2013-07-30 2014-07-29 画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム

Country Status (1)

Country Link
JP (1) JP2015044803A (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534119B2 (en) 2019-10-31 2022-12-27 Canon Medical Systems Corporation Analysis apparatus and analysis program

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009062287A (ja) * 2007-09-04 2009-03-26 Taiho Yakuhin Kogyo Kk ウラシル化合物又はその塩、これらを有効成分として含有するイメージング剤、およびこれらを有効成分として含有する腫瘍診断をするためのイメージング剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009062287A (ja) * 2007-09-04 2009-03-26 Taiho Yakuhin Kogyo Kk ウラシル化合物又はその塩、これらを有効成分として含有するイメージング剤、およびこれらを有効成分として含有する腫瘍診断をするためのイメージング剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. LABEL COMPD. RADIOPHARM., vol. Vol.51, JPN6018001449, 2008, pages 384 - 387 *
NUCLEAR MEDICINE AND BIOLOGY, vol. Vol.37, JPN6018001447, 2010, pages 427 - 432 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534119B2 (en) 2019-10-31 2022-12-27 Canon Medical Systems Corporation Analysis apparatus and analysis program

Similar Documents

Publication Publication Date Title
Dijkers et al. Biodistribution of 89Zr‐trastuzumab and PET imaging of HER2‐positive lesions in patients with metastatic breast cancer
Thackeray et al. Targeting post-infarct inflammation by PET imaging: comparison of 68Ga-citrate and 68Ga-DOTATATE with 18F-FDG in a mouse model
EP3856261A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
Samnick et al. Initial clinical investigation of [18F] tetrafluoroborate PET/CT in comparison to [124I] iodine PET/CT for imaging thyroid cancer
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
Dunphy et al. First-in-human trial of epichaperome-targeted PET in patients with cancer
WO2012161177A1 (ja) 腫瘍の画像診断用標識誘導体
Lawrence et al. PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives
Aggarwal et al. Real-time transferrin-based PET detects MYC-positive prostate cancer
Riedl et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort
van Elmpt et al. Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities
CN1950329B (zh) 放射性酪氨酸衍生物、其制造方法、其使用、正电子成像用标识剂和肿瘤的恶性度评价药剂
Zhang et al. Clinical translation of a dual-integrin αvβ3-and CD13-Targeting PET tracer
JP2015044803A (ja) 画像診断剤、抗腫瘍効果予測装置、抗腫瘍剤効果予測方法及び抗腫瘍効果予測プログラム
KR20260049617A (ko) Cu-64 psma i＆t 주사를 사용하여 인간 대상체에서 전립선암을 검출하는 방법
Hino-Shishikura et al. Biodistribution and radiation dosimetry of [18F]-5-fluorouracil
RU2614235C2 (ru) Остеотропный радиофармацевтический препарат для пэт-визуализации
US11504439B2 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
Wang et al. The Preparation and Execution of Exploratory Human Studies on Novel 99mTc-Labeled Glucosamine Derivatives Containing Different Phenyl Isonitriles as Promising Tumor Imaging Agents
CN105294769B (zh) 用于骨骼系统疾病显像的99mTc标记的多胺基膦酸体系
Viertl et al. Increase of [18F] FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography
Ferlin et al. The role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) whole body scan (WBS) in the staging and follow-up of cancer patients: our first experience
Huang et al. Investigation of brain tumors using 18F-fluorobutyl ethacrynic amide and its metabolite with positron emission tomography
Sharp et al. PET/CT in the evaluation of neuroblastoma
Zeltchan et al. Development and study of 99mTc-1-Thio-D-glucose for visualization of malignant tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180816